

Revised forms for the submission of the Confidence-Building Measures

At the Third Review Conference it was agreed that all States Parties present the following declaration, later amended by the Seventh Review Conference:

Declaration form on Nothing to Declare or Nothing New to Declare for use in the information exchange

<i>Measure</i>	<i>Nothing to declare</i>	<i>Nothing new to declare</i>	<i>Year of last declaration if nothing new to declare</i>
A, part 1			
A, part 2 (i)		X	2016
A, part 2 (ii)		X	2016
A, part 2 (iii)		X	2016
B		X	2020
C			
E		X	2017
F	X		
G		X	2020

(Please mark the appropriate box(es) for each measure with a tick, and fill in the year of last declaration in the last column where applicable.)

Date: Thursday, April 14, 2022

State Party to the Convention: Hungary

Date of ratification/accession to the Convention: Wednesday, December 27, 1972

National point of contact:

Ministry of Foreign Affairs Department for Security Policy and Non-proliferation - bpnf@mfa.gov.hu

Address: 47 Bem rakpart, Budapest, H1027

Telephone: +36 1 4581105, +36 1 4581135

Fax: +36 1 457 5039

József Pete (Government Office of the Capital City Budapest) - pete.jozsef@bfkh.gov.hu
Chief Counsellor, CWC/BWC Officer

Address: 37-39 Németvölgyi út, Budapest, Hungary H1124

Telephone: +36 1 4585 601

Fax: +36 1 4585 869

Active promotion of contacts

The Third Review Conference agreed that States parties continue to implement the following:

"Active promotion of contacts between scientists, other experts and facilities engaged in biological research directly related to the Convention, including exchanges and visits for joint research on a mutually agreed basis."

In order to actively promote professional contacts between scientists, joint research projects and other activities aimed at preventing or reducing the occurrence of ambiguities, doubts and suspicions and at improving international cooperation in the field of peaceful bacteriological (biological) activities, the Seventh Review Conference encouraged States parties to share forward looking information, to the extent possible,

- on planned international conferences, seminars, symposia and similar events dealing with biological research directly related to the Convention, and

- on other opportunities for exchange of scientists, joint research or other measures to promote contacts between scientists engaged in biological research directly related to the Convention,

including through the Implementation Support Unit (ISU) within the United Nations Office for Disarmament Affairs.

Confidence-Building Measure "A"

Part 1 Exchange of data on research centres and laboratories

(Declaration not yet disclosed)

Part 2 Exchange of information on national biological defence research and development programmes

At the Third Review Conference it was agreed that States Parties are to implement the following:

In the interest of increasing the transparency of national research and development programmes on biological defence, the States Parties will declare whether or not they conduct such programmes. States Parties agreed to provide, annually, detailed information on their biological defence research and development programmes including summaries of the objectives and costs of effort performed by contractors and in other facilities. If no biological defence research and development programme is being conducted, a null report will be provided.

States Parties will make declarations in accordance with the attached forms, which require the following information:

- (1) The objective and summary of the research and development activities under way indicating whether work is conducted in the following areas: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research;
- (2) Whether contractor or other non-defence facilities are utilized and the total funding provided to that portion of the programme;
- (3) The organizational structure of the programme and its reporting relationships; and
- (4) The following information concerning the defence and other governmental facilities in which the biological defence research and development programme is concentrated:
 - (a) location;
 - (b) the floor areas (sqM) of the facilities including that dedicated to each of BL2, BL3 and BL4 level laboratories;
 - (c) the total number of staff employed, including those contracted full time for more than six months;
 - (d) numbers of staff reported in (c) by the following categories: civilian, military, scientists, technicians, engineers, support and administrative staff;
 - (e) a list of the scientific disciplines of the scientific/engineering staff;
 - (f) the source and funding levels in the following three areas: research, development, and test and evaluation; and
 - (g) the policy regarding publication and a list of publicly-available papers and reports.

Form A, part 2 (i)

National biological defence research and development programmes Declaration

(Declaration not yet disclosed)

Form A, part 2 (ii)

National biological defence research and development programmes

(Declaration not yet disclosed)

Form A, part 2 (iii)

National biological defence research and development programmes

(Declaration not yet disclosed)

Confidence-Building Measure "B"

Exchange of information on outbreaks of infectious diseases and similar occurrences caused by toxins

At the Third Review Conference it was agreed that States Parties continue to implement the following:

Exchange of information on outbreaks of infectious diseases and similar occurrences caused by toxins, and on all such events that seem to deviate from the normal pattern as regards type, development, place, or time of occurrence. The information provided on events that deviate from the norm will include, as soon as it is available, data on the type of disease, approximate area affected, and number of cases.

The Seventh Review Conference agreed the following:

No universal standards exist for what might constitute a deviation from the normal pattern.

Modalities

The Third Review Conference agreed on the following, later amended by the Seventh Review Conference:

1. Exchange of data on outbreaks that seem to deviate from the normal pattern is considered particularly important in the following cases:

- When the cause of the outbreak cannot be readily determined or the causative agent [10](#) is difficult to diagnose,
- When the disease may be caused by organisms which meet the criteria for risk groups III or IV, according to the classification in the latest edition of the WHO Laboratory Biosafety Manual,
- When the causative agent is exotic to a given geographical region,
- When the disease follows an unusual pattern of development,
- When the disease occurs in the vicinity of research centres and laboratories subject to exchange of data under item A,
- When suspicions arise of the possible occurrence of a new disease.

2. In order to enhance confidence, an initial report of an outbreak of an infectious disease or a similar occurrence that seems to deviate from the normal pattern should be given promptly after cognizance of the outbreak and should be followed up by annual reports. To enable States Parties to follow a standardized procedure, the Conference has agreed that Form B should be used, to the extent information is known and/or applicable, for the exchange of annual information.

3. The declaration of electronic links to national websites or to websites of international, regional or other organizations which provide information on disease outbreaks (notably outbreaks of infectious diseases and similar occurrences caused by toxins that seem to deviate from the normal pattern) may also satisfy the declaration requirement under Form B.

4. In order to improve international cooperation in the field of peaceful bacteriological (biological) activities and in order to prevent or reduce the occurrence of ambiguities, doubts and suspicions, States Parties are encouraged to invite experts from other States Parties to assist in the handling of an outbreak, and to respond favourably to such invitations, respecting applicable national legislation and relevant international instruments.

Form B

Information on outbreaks of infectious diseases and similar occurrences, that seem to deviate from the normal pattern^{[11](#)}

N/A

Confidence-Building Measure "C"

Encouragement of publication of results and promotion of use of knowledge

At the Third Review Conference it was agreed that States parties continue to implement the following:

Encouragement of publication of results of biological research directly related to the Convention, in scientific journals generally available to States parties, as well as promotion of use for permitted purposes of knowledge gained in this research.

Modalities

The Third Review Conference agreed on the following:

1. It is recommended that basic research in biosciences, and particularly that directly related to the Convention should generally be unclassified and that applied research to the extent possible, without infringing on national and commercial interests, should also be unclassified.

2. States parties are encouraged to provide information on their policy as regards publication of results of biological research, indicating, inter alia, their policies as regards publication of results of research carried out in research centres and laboratories subject to exchange of information under item A and publication of research on outbreaks of diseases covered by item B, and to provide information on relevant scientific journals and other relevant scientific publications generally available to States parties.

3. The Third Review Conference discussed the question of cooperation and assistance as regards the safe handling of biological material covered by the Convention. It concluded that other international forums were engaged in this field and expressed its support for efforts aimed at enhancing such cooperation.

Comments:

The list of relevant publications in the year 2021 by Hungary is the follows:

- Róka E, Khayer B, Kis Z, Kovács LB, Schuler E, Magyar N, Málnási T, Oravecz O, Pályi B, Pándics T, Vargha M. Ahead of the second wave: Early warning for COVID-19 by wastewater surveillance in Hungary. *Sci Total Environ*. 2021 Sep 10;786:147398. doi: 10.1016/j.scitotenv.2021.147398. Epub 2021 Apr 29.
- JH et al, 2021 Taxonomic update of phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales. *Arch Virol*. 2021 Dec;166(12):[3513-3566](#). doi: 10.1007/s00705-021-05143-6
- D Máthé, B Kiss, B Pályi, Z Kis, L Forgách, N Hegedűs, Z Varga, K Szigeti, The 3M Concept: Biomedical Translational Imaging from Molecules to Mouse to Man, *The EuroBiotech Journal* 5 (3), 155-160
- Kiss B, Kis Z, Pályi B, Kellermayer MSZ. Topography, Spike Dynamics, and Nanomechanics of Individual Native SARS-CoV-2 Virions. *Nano Lett*. 2021 Mar 24;21(6):[2675-2680](#). doi: 10.1021/acs.nanolett.0c04465. Epub 2021 Jan 21.
- Horváti K, Fodor K, Pályi B, Henczkó J, Balka G, Gyulai G, Kiss É, Biri-Kovács B, Senoner Z, Bősze S. Novel Assay Platform to Evaluate Intracellular Killing of Mycobacterium tuberculosis: In Vitro and In Vivo Validation. *Front Immunol*. 2021 Nov 12;12:750496. doi: 10.3389/fimmu.2021.750496. eCollection 2021.
- Ali, Omeralfaroug; Mézes Miklós; Balogh, Krisztián; Kovács, Melinda; Szabó, András
The Effects of Mixed Fusarium Mycotoxins at EU-Permitted Feed Levels on Weaned Piglets' Tissue Lipids, *TOXINS* 13: 7 Paper: 444, 26 p. (2021)
- Kócsó, Dániel J.; A li. Omeralfaroug; Kovács, Melinda; Mézes, Miklós; Balogh, Krisztián; Kachlek, Mariam L.; Bóta, Brigitta; Zeebone, Yarsmin Y.; Szabó. András

- A preliminary study on changes in heat shock protein 70 levels induced by Fusarium mycotoxins in rats: in vivo study, MYCOTOXIN RESEARCH 37 pp. 141-148. Paper: s12550-021-00425-z, 8 p. (2021)
- Szabó-Fodor, Judit; Szeitzné-Szabó, Mária; Bóta, Brigitta; Schieszl, Tamás; Angeli, Cserne; Gambacorta, Lucia; Solfrizzo, Michele; Szabó, András; Kovács, Melinda
Assessment of Human Mycotoxin Exposure in Hungary by Urinary Biomarker Determination and the Uncertainties of the Exposure calculation: A case study
FOODS 11 : 1 Paper: 11010015, 15 p. (2021)
 - Dobolyi, Cs., Inotai, K., Bata-Vidács, I., Sárkány, O., Csernus, O., Kocsubé, S., Tóth, B., Szekeres, A., Kukolya, J. Isolation and detailed Characterisation of the first sterigmatocystin hyperproducer mould strain in Hungary. ACTA ALIMENTARIA: AN INTERNATIONAL JOURNAL OF FOOD SCIENCE 50:247-258., (2021)
 - Papp, D.A., Kovács, T., Varga, A., Allaga, H., Vörös, M., Szekeres, A., Hamari, Zs., Vágvölgyi, Cs., Varga, M. Screening antagonistic effect of fluorescent Pseudomonads against *Aspergillusflavus*. ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA, 68: Supplement 1, 103-104.,2 p. (2021)
 - Bence Ivánovics, Gyöngyi Gazsi, Márta Reining, Izabella Berta, Szilárd Poliska, Márta Tóth, Apolka Domokos, Béla Nagy, Ádám Staszny, Mátyás Cserháti, Éva Csósz, Attila Bacsi, Zsolt Csenki-Bakos, András Ács, Béla Urbányi, Zsolt Czimmerer.
Embryonic exposure to low concentrations of aflatoxin B1 triggers global transcriptomic changes, defective yolk lipid mobilization, abnormal gastrointestinal tract development and inflammation in zebrafish. *Journal of Hazardous Materials* 416, 125788. <https://doi.org/10.1016/j.jhazmat.2021.125788>
 - Kövesi, Benjámin; Kulcsár, Szabina; Cserháti, Mátyás; Erdélyi, Márta; Ancsin, Zsolt; Zándoki, Erika; Mézes, Miklós; Balogh, Krisztián (2021).
Modification of the effects of aflatoxin B1 on the glutathione system and its regulatory genes by zeolite. *Acta Veterinaria Hungarica* 69: 1 pp. 23-30. <https://doi.org/10.1556/004.2021.00002>
 - Garai E, Risa A, Varga E, Cserháti M, Kriszt B, Urbányi B, Csenki Z. (2021)
Evaluation of the Multimycotoxin-Degrading Efficiency of *Rhodococcus erythropolis* N11 Strain with the Three Step Zebrafish Microinjection Method. *International Journal of Molecular Sciences* 2(2):724. <https://doi.org/10.3390/ijms22020724>
 - Kulcsár S. Kövesi B., Balogh K., Zándoki E. Ancsin Z. Erdélyi M. Mézes M. (2021):
Effects of Fusarium mycotoxin exposure on lipid peroxidation and glutathione redox system in the Jiver of laying hens. *Antioxidants* 10, 8 Paper 1313, 10p. <https://doi.org/10.3390/antiox10081313>
 - Bajusz, D., Wade, W. S., Satala, G., Bojarski, A. J., Ilas, J., Ebner, J., ... Keserű, G.M. (2021). Exploring protein hotspots by optimized fragment pharmacophores. *NATURE COMMUNICATIONS*, 12(1).
 - Bereczki, I., Papp, H., Kuczmog, A., Madai, M., Nagy, V., Agócs, A., ... Borbás, A. (2021). Natural Apocarotenoids and Their Synthetic Glycopeptide Conjugates Inhibit SARS-CoV-2 Replication. *PHARMACEUTICALS*, 14(11). <http://doi.org/10.3390/ph14111111>
 - Jakab, F. (2021). Járvány, vírus, Virologiai Nemzeti Laboratórium. *SCIENTIA ET SECURITAS*, 2(1), 62-67 <https://doi.org/10.1556/112.2021.00013>
 - Kemenesi, G., Tóth, G. E., Bajusz, D., Keserű, G. M., Terhes, G., Burián, K., ... Jakab, F. (2021). Effect of An 84-bp Deletion of the Receptor-Binding Domain on the ACE2 Binding Affinity of the SARS-CoV-2 Spike Protein: An In Silico Analysis. *GENES*, 12(2) <https://doi.org/10.3390/genes/12020194>
 - Lanszki, Z., Zana, B., Zeghib, S., Jakab, F., Szabó, N., & Kemenesi, G. (2021).
Prolonged infection of canine distemper virus in a mixed-breed dog. *VETERINARY SCIENCES*, 8(4). <https://doi.org/10.3390/vetsci8040061>
 - Madai, M., Horváth, G., Herczeg, R., Somogyi, B., Zana, B., Földes, F., ... Jakab, F. (2021). Effectiveness Regarding Hantavirus Detection in Rodent Tissue Samples and Urine. *VIRUSES*, 13(4). <https://doi.org/10.3390/v13010570>
 - Szabó, Z., Szabó, T., Bodó, K., Kemenesi, G., Földes, F., Kristóf, K., ... Lacza, Z. (2021). Comparison of virus neutralization activity and results of 10 different anti SARS-Co V-2 serological tests in COVID-19 recovered plasma donors. *PRACTICAL LABORATORY MEDICINE*, 25. <https://doi.org/10.1016/j.plabm.2021.e00222>
 - Zeghib, S., Somogyi, B. A., Zana, B., Kemenesi, G., Herczeg, R., Derrar, F., & Jakab, F. (2021). The Algerian Chapter of SARS-CoV-2 Pandemic: An Evolutionary, Genetic, and Epidemiological Prospect.

VIRUSES, 13(8). <https://doi.org/10.3309/v13081525>

- Bakó, C., Balázs, V. L., Takács, G., Pallos, J. P., Pál, S., Kocsis, B., ... Horváth, G. (2021). Combination of Analytical and Statistical Methods in Order to Optimize Antibacterial Activity of Clary Sage Supercritical Fluid Extracts. *MOLECULES*, 26(21). <https://doi.org/10.3390/molecules26216449>
- Balázs, V. L., Nagy-Radványi, L., Filep, R., Kerekes, E., Kocsis, B., Kocsis, M., & Farkas, Á. (2021). In Vitro Antibacterial and Antibiofilm Activity of Hungarian Honeys against Respiratory Tract Bacteria. *FOODS*, 10(7) <https://doi.org/10.3390/foods10071632>
- Balázs, V. L., Nagy-Radványi, L., Kocsis, B., & Farkas, Á. (2021). Fajtamézek gátló hatása *Pseudomonas* bakteriális biofilm képzésére = Anti-*Pseudomonas* activity of unifloral honeys. In XIX. Szentágotthai János Multidiszciplináris Konferencia és Hallgatói Verseny: Absztrakt kötet = XIX. János Szentágotthai Multidisciplinary Conference and Student Competition: Book of Abstracts (pp. 244-244).
- BUDÁN, F., NAN, M., KOCSIS, B., & LACZKÓ-ZÖLD, E. (2021). ANTIMICROBIAL ACTIVITY AND POTENTIAL SECONDARY SIGNAL TRANSDUCTION MECHANISMS OF *ELECAMPANE* (*Inula helenium* L.) ROOT EXTRACT. *PLANT CELL BIOTECHNOLOGY AND MOLECULAR BIOLOGY*, 22(7-8), 86-92.
- Dandé, Á., Nöt, L. G., Bücs, G., Kocsis, B., Lőrinczy, D., & Wiegand, N. (2021). Efficacy of microbiological culturing in the diagnostics of joint and periprosthetic infections. *INJURY: INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED*, 52(Suppl 1), S48-S52. <https://doi.org/10.1016/j.injury.2020.02.058>
- Hammoud, S., Haitham, K., Afshin, Z., & Bela, K. (2021). A Survey of Nurses'. Awareness of Infection Control Measures in Baranya County, Hungary. In 10th Jubilee Interdisciplinary Doctoral Conference (p.249)
- Hammoud, S., Onchonga, D., Amer, F., & Kocsis, B. (2021). The Burden of Communicable Diseases in Lebanon: Trends in the Last Decade. In Medical Conference for PhD Students and Experts of clinical Sciences 2021 (p.18)
- Kocsis, B., Deutsch-Nagy, L., Kilár, F., Kilár, A., Makszin, L., & Urbán, P. (2021). *Shigella sonnei* mutánsok az antibiotikumalapoktatás szolgálatában. In METT25 a Magyar Elválasztástudományi Társaság jubileumi konferenciája (p. 59).
- Mező, E., Bufa, A., Madarászné, H. I., Balogh-Hartmann, F., Kilár, F., Kocsis, B., & Makszin, L. (2021a). Környezeti tényezők változásainak hatása baktériumok zsírsavösszetételére. In 10. Jubileumi Interdiszciplináris Doktorandusz Konferencia = 10th Jubilee Interdisciplinary Doctoral Conference (p. 301).
- Mező, E., Bufa, A., Madarászné, H. I., Balogh-Hartmann, F., Kilár, F., Kocsis, B., & Makszin, L. (2021b). Orvosi szempontból fontos baktériumok zsírsav-összetételének vizsgálata GC-MS módszerrel. In METT25 a Magyar Elválasztástudományi Társaság jubileumi konferenciája.
- Varga, A., Kocsis, B., Sipos, D., Kása, P., Vigvári, S., Pál, S., ... Péterfi, Z. (2021). How to Apply FMT More Effectively, Conveniently and Flexible-A Comparison of FMT Methods. *FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY* 11. <https://doi.org/10.3389/fcimb.2021.657320>

Confidence-Building Measure "D"

(Deleted)

Confidence-Building Measure "E"

Declaration of legislation, regulations and other measures

At the Third Review Conference the States parties agreed to implement the following, later amended by the Seventh Review Conference:

As an indication of the measures which they have taken to implement the Convention, States parties shall declare whether they have legislation, regulations or other measures:

- (a) To prohibit and prevent the development, production, stockpiling, acquisition or retention of the agents, toxins, weapons, equipment and means of delivery specified in Article I of the Convention, within their territory or anywhere under their jurisdiction or under their control anywhere;
- (b) In relation to the export or import of micro-organisms pathogenic to man, animals and plants or of toxins in accordance with the Convention;
- (c) In relation to biosafety and biosecurity.

States parties shall complete the attached form (Form E) and shall be prepared to submit copies of the legislation or regulations, or written details of other measures on request to the Implementation Support Unit (ISU) within the United Nations Office for Disarmament Affairs or to an individual State party. On an annual basis States parties shall indicate, also on the attached form, whether or not there has been any amendment to their legislation, regulations or other measures.

Form E

Declaration of legislation, regulations and other measures

<i>Relating to</i>	<i>Legislation</i>	<i>Regulations</i>	<i>Other measures¹²</i>	<i>Amended since last year</i>
(a) Development, production stockpiling, acquisition or retention of microbial or other biological agents, or toxins, weapons, equipment and means of delivery specified in Article I	yes	yes	no	no
(b) Exports of micro-organisms ¹³ and toxins	yes	yes	no	no
(c) Imports of micro-organisms ¹³ and toxins	yes	yes	no	no
(d) Biosafety ¹⁴ and biosecurity ¹⁵	yes	yes	no	no

Additional information to Form E:

Hungary signed the Biological and Toxin Weapons Convention in 1972 and ratified it in 1975. Detailed regulation of the implementation, however, followed much later when Government Decree 21/2013 (I. 30.) was issued in January 2013.

The Decree formalized the hitherto implementation mechanism, which was based on a general understanding of the roles and responsibilities of the various actors of the administrative system and subsequently their role in the implementation of the obligations undertaken in the BTWC. Throughout the period from 1975 to 2010 the implementation of the BTWC was on the agenda of various inter-departmental committees. Hungary's biological and chemical industry is relatively small and those involved in research, production and licensing form a small community. Members of these various committees, whose portfolio included the BTWC among other similar or related issues were in contact with other stakeholders daily.

Until January 2013 the Ministry of Foreign Affairs was responsible for the collection of data and submission of the CBM reports. The GD 21/2013 (I. 30.), however, assigns this responsibility to the Government Office of the Capital City Budapest (GO). The GO is in charge of authoritative-administrative tasks in the field of (a) state administration of foreign trade, (b) surveillance of production and service in the armament industry, (c) certain tasks in trade, (d) market surveillance, (e) surveillance of public warehouses, (f) assaying and hallmarking of precious metal and (g) metrology. The Department of Trade, Defence Industry, Export Control and Precious Metal Assay of the GO became also the national authority for the implementation of the Common Commercial Policy of the EU as well as the National Authority for the implementation of the CWC.

Based on national and EU laws, the Department licenses and controls the foreign trade of military and dual-use products (including human, animal and plant pathogens and toxins, as well as dual-use chemical and biological equipment) and licenses the production of military products and related services following the Hungarian and EU foreign and security policy. The Department keeps an up-to-date list and data on the activities of all stakeholders relevant to the implementation of the BTWC.

Confidence-Building Measure "F"

Declaration of past activities in offensive and/or defensive biological research and development programmes

In the interest of increasing transparency and openness, States parties shall declare whether or not they conducted any offensive and/or defensive biological research and development programmes since 1 January 1946.

If so, States parties shall provide information on such programmes, in accordance with Form F.

Form F

Declaration of past activities in offensive and/or defensive biological research and development programmes

1. Date of entry into force of the Convention for the State Party.

Wednesday, December 27, 1972

2. Past offensive biological research and development programmes:

- N/A

- Period(s) of activities

N/A

- Summary of the research and development activities indicating whether work was performed concerning production, test and evaluation, weaponization, stockpiling of biological agents, the destruction programme of such agents and weapons, and other related research.

N/A

3. Past defensive biological research and development programmes:

- N/A

- Period(s) of activities

N/A

- Summary of the research and development activities indicating whether or not work was conducted in the following areas: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination, and other related research, with location if possible.

N/A

Confidence-Building Measure "G"

Declaration of vaccine production facilities

To further increase the transparency of biological research and development related to the Convention and to broaden scientific and technical knowledge as agreed in Article X, each State party will declare all facilities, both governmental and non-governmental, within its territory or under its jurisdiction or control anywhere, producing vaccines licensed by the State party for the protection of humans. Information shall be provided on Form G attached.

Form G

Declaration of vaccine production facilities

N/A

Notes

1. World Health Organization
2. World Organization for Animal Health.
3. The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.
4. For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form A, part 2 (iii)".
5. In accordance with the latest edition of the WHO Laboratory Biosafety Manual, or equivalent.
6. Microorganisms pathogenic to humans and/or animals
7. In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.
8. In accordance with the latest edition of the WHO Laboratory Biosafety Manual and/or the OIE Terrestrial Manual or other equivalent internationally accepted guidelines.
9. Including viruses and prions.
10. It is understood that this may include organisms made pathogenic by molecular biology techniques, such as genetic engineering.
11. See paragraph 2 of the chapeau to Confidence-Building Measure B.
12. Including guidelines.
13. Micro-organisms pathogenic to man, animals and plants in accordance with the Convention.
14. In accordance with the latest version of the WHO Laboratory Biosafety Manual or equivalent national or international guidance.
15. In accordance with the latest version of the WHO Laboratory Biosecurity Guidance or equivalent national or international guidance.